Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Gelesis LLC is active in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are split between 2 distinct examiners, ensuring that no single examiner is overwhelmed by the company's current filings. ANDREA STEFFEL OLSON is the busiest examiner, holding 1 busiest examiner pending action. This distribution shows that the company's active matters are being processed independently by different individuals, which can lead to varied prosecution timelines.
The portfolio is also divided across 2 distinct art units, suggesting that the company's innovations span multiple technical classifications. Because the 2 pending office actions are handled by 2 distinct examiners in 2 distinct art units, Gelesis LLC faces a diversified examination environment. This structure prevents a single art unit's policy from dictating the outcome of the entire active portfolio. Practitioners can expect that the results of these matters will be independent of each other within the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OLSON, ANDREA STEFFEL | 1 | 62.4% | -11.9% |
| LI, CHANGQING | 1 | 29.2% | +33.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17981620 | Methods and Compositions for Weight Management and for Improving Glycemic Control | LI, CHANGQING | 63d |
| 18663301 | Method for Producing Hydrogels | OLSON, ANDREA STEFFEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17981620 | Methods and Compositions for Weight Management and for Improving Glycemic Control | LI, CHANGQING | 63d |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18663301 | Method for Producing Hydrogels | OLSON, ANDREA STEFFEL | 1693 | §102§112Other | Non-Final OA | — | Pending | May 14, 2024 |
| 17981620 | Methods and Compositions for Weight Management and for Improving Glycemic Control | LI, CHANGQING | 1791 | §103 | Non-Final OA | 63d | Pending | Nov 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGelesis LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Andrea Steffel Olson has the most, with 1 of Gelesis LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
